

Opinion Leader

Speaker Series



**Precision
Medicine**



**Pathways &
Guidelines**



**Evolving
Quality**

Genentech
A Member of the Roche Group

BIO/080718/0112
©2018 Genentech Inc., South San Francisco, CA

Precision Medicine



Precision medicine is an emerging paradigm of oncology treatment in which the genetic mutations in a patient's tumor drive the treatment strategy.¹ This topic will address implementation of precision medicine in the clinic, the medical and financial impact of precision medicine, and potential developments in the field.



Lincoln Nadauld, MD, PhD

Director, Cancer Genomics Program, Intermountain Healthcare
Salt Lake City, Utah

Dr. Nadauld is Executive Director of Precision Medicine and Precision Genomics at Intermountain Healthcare, an integrated healthcare system, where he oversees the clinical implementation of precision medicine across 22 hospitals and 180 physician clinics.

Dr. Nadauld is a Visiting Scholar at Stanford University School of Medicine in the Division of Oncology, focusing on cancer genomics and personalized cancer medicine. His work has been published in journals such as Nature Medicine, Journal of Clinical Oncology, and Genome Medicine. He also serves on the board of directors of the Gastric Cancer Foundation and reviews grant applications on behalf of the US Department of Defense.

Dr. Nadauld received a bachelor of science degree from Brigham Young University and a combined MD/PhD from the University of Utah. He completed clinical training in medical oncology at Stanford University School of Medicine, where he also completed a postdoctoral fellowship in solid tumor genomics.



Howard McLeod, PharmD

Medical Director, DeBartolo Family Personalized Medicine Institute
Moffitt Cancer Center
Tampa, Florida

Dr. McLeod is Medical Director of the DeBartolo Family Personalized Medicine Institute and Chair of the Department of Individualized Cancer Management at Moffitt Cancer Center.

Dr. McLeod is Moffitt's first cancer research endowed chair, as established by the Florida Legislature. He has been awarded more than \$16 million in grants as a principal investigator and more than \$80 million in grants as a coinvestigator for research studies funded by the National Institutes of Health. He has authored over 550 peer-reviewed papers, book chapters, and reviews and has given over 1000 invited lectures in 42 countries.

Dr. McLeod received his doctor of pharmacy degree from Philadelphia College of Pharmacy and Science. He completed a clinical research fellowship at St Jude Children's Research Hospital and a medical oncology research fellowship at the University of Glasgow.



Edward S. Kim, MD

Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute Carolinas HealthCare System
Charlotte, North Carolina

Edward S. Kim, MD, is the chair of Solid Tumor Oncology and Investigational Therapeutics, the medical director of the Clinical Trials Office, and the Donald S. Kim Distinguished Chair for Cancer Research at the Levine Cancer Institute, Carolinas HealthCare System in Charlotte, NC.

Dr. Kim specializes in biomarkers and novel targeted agents for cancer treatment and prevention and has expertise in lung, head, and neck cancers. He is author or coauthor of more than 100 published articles, book chapters, and reviews. He chaired the Department of Defense Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) personalized medicine program in lung cancer.

Dr. Kim received his bachelor of science and medical degrees from the Honors Program in Medical Education (HPME) at Northwestern University, his residency at Baylor College of Medicine, and his fellowship in medical oncology at UT MD Anderson Cancer Center.

Pathways and Guidelines



Clinical pathways are evidence-based treatment protocols for delivering quality cancer care to patients with specific disease types and stages.² Pathways can serve as a tool for improving the quality of care and reducing costs.² This topic will cover trends in and implementation of pathway development and the future of oncology care guidelines.



Michael Kolodziej, MD

Vice President and Chief Innovation Officer, ADVI Health
Washington, DC

Dr. Kolodziej is Vice President and Chief Innovation Officer at ADVI Health. His work focuses on supporting alternative payment programs, including the Oncology Care Model and private payer initiatives.

Dr. Kolodziej has over 20 years of experience, including former positions as Associate Professor at the University of Oklahoma, Chairman of the US Oncology Network Pharmacy and Therapeutics Executive Committee, National Medical Director of Managed Care Strategy at Flatiron Health, and National Medical Director of Oncology Strategies at Aetna.

Dr. Kolodziej received his medical degree from the Washington University School of Medicine and completed his residency and oncology fellowship at the Hospital of the University of Pennsylvania. He is board certified in internal medicine, hematology, and medical oncology and has published more than 75 medical journal articles, abstracts, and book chapters.

Evolving Quality



A shift from volume to value is under way in oncology, and data are rapidly accruing to help measure and define value and high-quality care.³ This topic will cover the impact of care coordination and standardization and lessons learned from care coordination models as well as share best practices for the future.



Julia Trosman, PhD, MBA

Cofounder and Co-Director, Center for Business Models in Healthcare
Assistant Adjunct Professor, Northwestern University Feinberg School of Medicine
Assistant Adjunct Professor, UCSF School of Pharmacy
Chicago, Illinois

Dr. Trosman is cofounder and co-director of the Center for Business Models in Healthcare, a health services research organization focused on personalized care models and precision medicine in oncology. She holds adjunct faculty appointments at the University of California, San Francisco (UCSF) School of Pharmacy, and the Feinberg School of Medicine at Northwestern University.

Dr. Trosman's work is focused on developing and implementing personalized oncology care delivery models and related reimbursement structures that address challenges of team-based care, timely and coordinated care delivery and patient engagement. She is one of the authors of the 4R in Oncology Model, developed jointly with Northwestern University. Dr. Trosman leads a number of pilots and implementations of the 4R Model with cancer centers across the U.S.

In collaboration with the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Dr. Trosman studies adoption and reimbursement of precision medicine, with the current emphasis on healthcare system and reimbursement policy implications of genomic sequencing, including comprehensive tumor profiling and hereditary cancer testing.

Dr. Trosman holds an MBA degree from Kellogg School of Management, Northwestern University, and a PhD in systems engineering from the Law and Economics Institute (Russia).

1. U.S. National Library of Medicine. What is precision medicine? <https://ghr.nlm.nih.gov/primer/precisionmedicine/definition>. Accessed May 11, 2018.

2. Zon RT, et al. American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology. J Oncol Pract. 2016;12(3): 261-266.

3. Delivering high-quality cancer care. http://nationalacademies.org/hmd/~media/Files/Report%20Files/2013/Quality-Cancer-Care/qualitycancercare_rb.pdf. Accessed March 23, 2018.